Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

about

Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?

P2860

Q26779680-5D058503-4E38-435B-9BE3-F524771B3EFA

P2860

Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

Item

http://www.wikidata.org/entity/Q38525320

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

@en

type

Item

label

Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

@en

prefLabel

Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

@en

P1476

Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

@en

P2093

Hong-Yu Yuan

http://www.w3.org/2001/XMLSchema#string

Ji-Fu Wei

http://www.w3.org/2001/XMLSchema#string

Ling Meng

http://www.w3.org/2001/XMLSchema#string

Xiao-Lan Zhang

http://www.w3.org/2001/XMLSchema#string

Xue-Hui Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

What is causing my arthritis, doctor? A glimpse beyond the usual suspects in the pathogenesis of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Advances in the treatment of rheumatoid arthritis.

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs

Genetics and epigenetics of rheumatoid arthritis

[Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns].

Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.

Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists.

P304

909-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2015.1044972

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26066366

http://www.w3.org/2001/XMLSchema#string

P921

patent

Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

about

P2860

P2860

Analysis of patents on anti-rheumatoid arthritis therapies issued in China.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921